17 Jun 2013
US Patent Granted Covering use of VEGFR-3
04 Jun 2013
VGX-100 Phase 1 Oncology Trial Presented at ASCO 2013
27 May 2013
Change of Director’s Interest Notice
24 May 2013
Open Briefing: VGX-300 Potential in AMD
23 May 2013
Change of Director’s Interest Notice
20 May 2013
Change of Director’s Interest Notice
17 May 2013
Progress of VGX-100 Phase 1 trial to be presented at ASCO
09 May 2013
VEGF-C shown to have major role in Age-Related Macular Degeneration (AMD)
08 Mar 2013
Circadian grants world-wide licence to Santa Cruz Biotechnology Inc
06 Mar 2013
Edison Research publishes updated analysis on Circadian. Values the company at $1.93/share
27 Feb 2013
Circadian commences worldwide marketing & sales of unique VEGF-C & VEGF-D products as research reagents
25 Feb 2013
Open Briefing: Interview with CEO & MD Robert Klupacs on H1 Results & Outlook
22 Feb 2013
Appointment of CFO and Company Secretary
20 Feb 2013
Resignation of CFO and Company Secretary
18 Feb 2013
Half Year Report & Accounts
07 Feb 2013
R&D Tax Incentive - Circadian Receives $1.3m
04 Feb 2013
VGX-100 Phase 1 Clinical Trial Program Update
17 Dec 2012
Change of Director’s Interest Notice
11 Dec 2012
Open Briefing interview with MD & CEO Robert Klupacs
21 Nov 2012
Change of Director's Interest Notice
20 Nov 2012
Results of Annual General Meeting 20 November 2012
20 Nov 2012
CEO AGM Presentation to shareholders
20 Nov 2012
Chairman's Address to Shareholders
15 Nov 2012
Circadian grants world-wide licence to Bio-Rad to market research products
08 Nov 2012
VGX-100 Poster Presentation at EORTC
07 Nov 2012
VGX-100 Top 10 Oncology Candidate Windhover Conference
02 Nov 2012
AusBiotech Presentation Company Update
22 Oct 2012
Annual Report / Notice of AGM and Proxy
02 Oct 2012
Dr Errol Malta – Resignation as Director
24 Sep 2012
Open Briefing - FY2012 Results and Outlook
24 Aug 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
23 Aug 2012
Preliminary Final Report (Appendix 4E) - Financial Year Ended 30 June 2012
17 Jul 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
12 Jul 2012
Change of Director’s Interest Notice
10 Jul 2012
Change of Director’s Interest Notice
09 Jul 2012
Alpha Securities Analyst Investment Research Report Available on Circadian Website
27 Jun 2012
Commercial Launch of CUP Test
22 Jun 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
12 Jun 2012
Circadian makes $1M Share Placement
12 Jun 2012
Reinstatement to Official Quotation
07 Jun 2012
Suspension Confirm
07 Jun 2012
Suspension Request
05 Jun 2012
Request for Trading Halt
01 Jun 2012
Updated Corporate Presentation
27 Apr 2012
Notice of Ceasing to be a Substantial Holder
02 Apr 2012
Change of Director’s Interest Notice
29 Mar 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
15 Mar 2012
Analyst Investment Research Report Available on Circadian Website
09 Mar 2012
Positive data published on performance of Circadian’s Cancers of Unknown Primary Diagnostic Test
20 Feb 2012
Open Briefing with CEO & MD Robert Klupacs - Half Year Results and Outlook
16 Feb 2012
Half-Year Financial Report & Operational Achievements
30 Jan 2012
VGX-100 identified as potential new therapy for improving corneal graft survival
09 Jan 2012
Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients
21 Dec 2011
Change of Director’s Interest Notice
19 Dec 2011
Finance News Network Interview with CEO Available on Circadian Website
13 Dec 2011
Change of Director’s Interest Notice
25 Nov 2011
Final Director’s Interest Notice
24 Nov 2011
Results of Annual General Meeting 24 November 2011
24 Nov 2011
Annual General Meeting Presentation 24 November 2011
24 Nov 2011
Chairman's Address to Annual General Meeting 24 November 2011
15 Nov 2011
Open Briefing with CEO & MD Robert Klupacs: CEO on IND status for VGX-100
31 Oct 2011
Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors
25 Oct 2011
Change of Director's Interest Notice
24 Oct 2011
Notice of Annual General Meeting and Explanatory Memorandum
20 Oct 2011
Change of Director's Interest Notice
18 Oct 2011
Final Director's Interest Notice
11 Oct 2011
Analyst Investment Research Reports Available on Circadian Website
10 Oct 2011
Healthscope commences clinical validation study of Circadian's Cancer Diagnostic
03 Oct 2011
Retirements from Circadian Board of Directors
30 Sep 2011
Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors
15 Sep 2011
Open Briefing with CEO & MD Robert Klupacs: FY12 Outlook and VGX-100 Progress
13 Sep 2011
VGX-100 identified as potential new therapy for Dry Eye Disease
12 Sep 2011
Circadian makes key appointment in clinical trials management
09 Sep 2011
Change of Director's Interest Notice
07 Sep 2011
Change of Director's Interest Notice
07 Sep 2011
Change of Director's Interest Notice
06 Sep 2011
Change of Director's Interest Notice
31 Aug 2011
Change in Substantial Holding for Optiscan Imaging Limited - Update
31 Aug 2011
Change of Director's Interest Notice
30 Aug 2011
Change of Director's Interest Notice
24 Aug 2011
Preliminary Final Report Appendix 4E Financial Year Ended 30 June 2011
25 Jul 2011
Change of Director's Interest Notice
18 Jul 2011
Change of Directors Interest Notice
14 Jul 2011
Open Briefing with CEO & MD Robert Klupacs
16 Jun 2011
Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications
14 Jun 2011
Circadian launches Level 1 ADR program and OTCQX Quotation in US
10 Jun 2011
Substantial Holding Notice for Antisense Therapeutics Limited
07 Jun 2011
VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients
30 May 2011
Analyst Investment Research Reports Available on Circadian Website
18 Apr 2011
Circadian Technologies (Small Cap Showcase 2011) - Robert Klupacs Presentation
Read More
07 Apr 2011
Open Briefing with CEO & MD Robert Klupacs on First Phase I Clinical Trial of IMC - 3C5
06 Apr 2011
Circadian's VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer
06 Apr 2011
Circadian's partner ImClone Systems commences first Phase 1 clinical trial of VEGFR-3 antibody IMC-3C5
22 Mar 2011
New issue announcement, application for quotation of additional securities and agreement
15 Feb 2011
31 December 2010 Half-Year Financial Report & Operational Achievements
14 Feb 2011
Finance News Network Interview with Circadian CEO Robert Klupacs
02 Feb 2011
Circadian Launches First Diagnostic for LAM Lung Disease with U.S. Partner
17 Jan 2011
VEGF-D Licence Agreement Open Briefing
13 Jan 2011
Chugai Pharmaceutical of Japan Grants Circadian Worldwide Licence to its VEGF-D Intellectual Property Estate
11 Jan 2011
2011 Biotech Showcase
